Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-EARLY: Acoramidis for Transthyretin Amyloidosis Prevention in the Young
NCT06563895Phase 3Recruiting
- Sponsor
- BridgeBio Pharma
- Start
- May 2025
- Primary completion
- Oct 2031
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Acoramidis with Placebo (2 arms). Primary endpoint: Time to development of ATTR (ATTR-CM or ATTR-PN) at 7 years. Started May 2025; status: recruiting.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT06563895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563895.